A lmost 1 century after the original observation of Drury and Szent-Györgyi [1] , that it exerts cardiovascular effects, adenosine remains a subject of intensive studies, not only in the cardiovascular system but in many other areas of biology and medicine [2] .
The first observations that adenosine exerts proangiogenic effects were made almost 30 years ago, when Teuscher and Weidlich [2] showed in Boyden chamber experiments that adenosine exerts chemotactic effects in porcine endothelial cells [3] . Subsequent studies have demonstrated the proangiogenic effect of adenosine in various experimental models, ranging from chicken chorioallantoic membranes to mammalian systems of postischemic angiogenesis and tumor angiogenesis (overviewed in ref. [4] ).
The proangiogenic effects of adenosine include direct actions on endothelial cells and indirect effects via multiple cell types (such as smooth muscle cells, monocytes/ macrophages/foam cells, and mast cells; see Fig. 1A ). Part of the direct angiogenic effects of adenosine are directly related to the regulation by adenosine of endothelial signaling pathways, thereby affecting cell cycle, cell division, and cell migration. However, it appears that a substantial portion of adenosine's actions is related to its ability to induce the release of the proangiogenic hormone VEGF from macrophages/monocytes, mast cells, as well as from the endothelial cells themselves. Adenosine has also been shown to stimulate the production of other proangiogenic hormones, such as IL-8, bFGF, and IGF-1. Thus, the proangiogenic effects of adenosine are the result of a complex network of autocrine and paracrine actions in the vascular microenvironment that ultimately result in endothelial cell proliferation, migration, tube formation, and the formation of new blood vessels. All four adenosine receptor subtypes (A 1 , A 2A , A 2B , A 3 ) have been implicated in these responses (with some speciesdependent, cell-type, and modeldependent differences that remain to be elucidated further; see Fig. 1A ). The physiologic and pathophysiological significance of these processes ranges from postischemic neovascularization to tumor angiogenesis and wound healing [2, 4] .
TSP-1 is generally viewed as an antiangiogenic molecule. Identified over 25 years ago, TSP-1 has been shown to antagonize the growth-promoting effects of bFGF and of VEGF and is widely regarded as an endogenous inhibitor of endothelial cell proliferation and angiogenesis (overviewed in ref. [5] ). Its mode of action involves direct binding to VEGF, inhibition of endothelial cellcycle progression through CD36, and inhibition of the endothelial cell-derived vasodilator and proangiogenic mediator NO. Before the report of Ernens and colleagues [6] in the current issue of the Journal of Leukocyte Biology, the only connection between adenosine's proangiogenic effect and TSP-1 was made by Cronstein and colleagues [7] , who, working in HUVECs, reported that adenosine, as well as selective A 2A receptor agonists, suppress endothelial cell TSP-1 expression and secretion. The same group demonstrated that TSP-1 antibodies and CD36 antibodies prevent the ability of A 2A receptor agonists to stimulate HUVEC proliferation [7] . These data led to the conclusion that adenosine exerts proangiogenic effects through inhibiting the formation of the antiangiogenic hormone TSP-1. It may be worth mentioning that the study by Cronstein and colleagues [7] did not include positive control studies to test the effects of authentic TSP-1 on endothelial cell proliferation in their HUVEC experimental system.
The current report presents a different facet to the proangiogenic effects of adenosine (as well as TSP-1). First, somewhat surprisingly, it shows that the effects of TSP-1, at lower concentrations (0.01-5 mg/ml) stimulates neovessel formation in a rat aortic ring angiogenesis assay in vitro [6] . Elevation of the concentration of TSP-1 to 10 mg/ml, on the other hand, tended to become inhibitory. It may seem surprising that after 20 years of intensive work on TSP-1, only a few studies have noticed that TSP-1 exerts proangiogenic effects at lower concentrations. Nevertheless, in a study published in 1997 in bovine endothelial cells, TSP-1, at 1-4 mg/ml, was found to stimulate the length of endothelial network formation, and the "canonical" inhibition of endothelial cell angiogenesis only ensued at higher concentrations, 10 mM and above [8] . Likewise, Motegi and colleagues [9] reported that TSP-1 stimulates endothelial cell migration at low concentrations (0.1-10 mg/ml), and it only becomes inhibitory at 25-100 mg/ml.
Next, Ernens and colleagues [6] showed that adenosine stimulates the production of TSP-1 by human macrophages, an effect that was attributed to 1 [10] . Further studies by Ernens and colleagues [6] showed that conditioned medium from adenosinetreated macrophages was proangiogenic and that this proangiogenic response was suppressed by TSP-1 antibodies. The study failed to quantify the amount of TSP-1 in the conditioned medium; therefore, it is unclear whether the proangiogenic effects seen in this system are mediated by TSP-1 or (more likely) by a combination of interacting factors and mediators-TSP-1 being one of them. Further studies using Matrigel assays and myocardial infarction models suggest that the adenosine/TSP-1 interaction may have relevance in vivo in the context of postischemic angiogenesis as well [6] . How then does adenosine promote angiogenesis via TSP-1? Does it work through the "older" model by inhibiting an antiangiogenic effect of TSP-1, or does it work through the "newer" model by stimulating the proangiogenic effect of TSP-1? Given the bell-shaped concentration response of TSP-1 on endothelial cell angiogenesis, these two models do not need to be mutually exclusive. For example, it is conceivable that adenosine enhances relatively low (proangiogenic, macrophage-derived) levels of TSP-1 at the lower half of the bell-shaped, doseresponse curve, whereas it inhibits higher (antiangiogenic, endothelial cellderived) levels of TSP-1 at the higher end of the same dose-response curve (Fig. 1B) . However, the testing of this hypothesis would require additional in vitro and in vivo experimentation, where potential bell-shaped, dose-response curves would need to be explored carefully; cell type-dependent and species-dependent differences may also be possible.
Taken together, the current report unveils novel facets and additional complexities of the "age-old" proangiogenic effects of adenosine and may open the door for a new direction of experimental, therapeutic approaches. Who says you can't teach new tricks to an old dog? [6] , and it can suppress the release of TSP-1 from endothelial cells [7] . Additional processes not depicted in this figure include the down-regulation by adenosine of various proangiogenic factors (e.g., TNF-a and soluble fms-like tyrosine kinase-1from macrophages or angiopoietin-2 from mast cells), hemodynamic effects (as increase in shear stress in vivo can also stimulate the production of NO, a proangiogenic mediator), and effects of adenosine on progenitor cells (adenosine has been shown to stimulate the homing of endothelial progenitor cells to the sites of tissue injury, thereby promoting angiogenesis in vivo). An additional mechanism not shown in the figure is that hypoxia/adenosine can also up-regulate various adenosine receptors on the responder cells, thereby further enhancing the proangiogenic response [2, 4] . Arrows with + indicate stimulatory interactions; arrows with -indicate inhibitory interactions. (B) Working hypothesis attempting to reconcile the literature on the proangiogenic effect of adenosine via modulation of TSP-1 production in various cell types. TSP-1 produces a bell-shaped concentration response on endothelial cell angiogenesis, with lower concentrations (perhaps produced by macrophages in a proinflammatory or postischemic microenvironment) proangiogenic and higher concentrations (perhaps produced by endothelial cells in other contexts) antiangiogenic. Adenosine may enhance the relatively low (proangiogenic, macrophage-derived) levels of TSP-1 (red arrow), whereas it may inhibit higher (antiangiogenic, endothelial cell-derived) levels of TSP-1 (green arrow).
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N HP are the missing link in translating biomedical research from bench to bedside. Indeed, they are often the strongest models for preclinical testing of therapeutic and vaccine candidates, likely providing the most accurate surrogates for whether candidate agents will-or will not-operate effectively in humans. The last decade has witnessed a growing appreciation for B cells as key targets in the development of therapeutics for autoimmune diseases, and B cells are, of course, the sole source of antibody titers required for effective prophylactic vaccines. Accordingly, extending B cell subset hierarchies established in mouse models to nonhuman primates-and then to analogous subsets defined in humans-will be key to leveraging information gained from studies in higher vertebrates.
Surprisingly, despite widespread use of NHP for preclinical and basic studies in diabetes, transplantation, cancer, and infection, detailed information about the numbers and representation, as well as the anatomic locales of B cell and plasma cell subsets, has remained rudimentary. For example, macaca species are commonly used models of human antibody responses to herpes virus, EBV, and SIV infection, yet most published reports to date have used comparatively minimal B cell subset analyses and/or small cohorts of uninfected animals. In this issue of JLB, Neumann et al. [1] take a step toward rectifying this with their report on B cell and plasmablast/plasma cell subsets in primary and secondary lymphoid tissues of healthy rhesus macaques. In addition to providing muchneeded, basic information about subset representation, their findings reveal intriguing, previously unappreciated, disparities in proportional representation of B-lineage populations from different anatomic sites. Furthermore, they provide a valuable comparison of fresh versus preserved blood and bone marrow from the same animals, revealing a preferential loss of CD27+ B cells incurred after cryogenic storage.
Similar to other recent reports, Neumann et al. [1] apply multicolor flow cytometry to rhesus macaque B cell subsetting and, like a concurrent report [2] , include assessments of activation molecules, chemokine receptors, and Igs in their analyses. In addition, the authors follow phenotyping schemes applied to human B cells and plasmablasts/plasma cells (reviewed in ref. [3] ). Three observations are noteworthy and foster thought about future applications. First, the distribution of B cells and plasma cells in bone marrow and secondary lymphoid organs is not necessarily mirrored in blood, consistent with findings in prior studies. A second and unexpected observation is that marrow from a flat bone shows a strikingly different B cell and plasmablast/plasma cell distribution pattern compared with marrow from a long bone. Finally, Neumann et al. [1] show that freezing blood or bone marrow samples leads to loss of CD27+ B cell subsets.
The proportions and phenotypes of peripheral blood B cell subsets do not necessarily reflect those in primary or secondary lymphoid organs. In confirming and extending other reports, Neumann et al. [1] find moderate to large differences in B cell subset and plasmablast/plasma cell frequencies when blood and other anatomic sites are compared [2, 4] (Fig. 1) . For example, naïve B cells comprise approximately one-
